Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

NCT03940833 is registered in ClinicalTrials.gov with Asclepius Technology Company Group (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT03940833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03940833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
Lead sponsor
Asclepius Technology Company Group (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2019
Completion date
May 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma